Amide Technologies
Cambridge
About Amide Technologies
Amide synthesizes peptides that are difficult to obtain through existing means, bridging the gap between traditional solid phase peptide synthesis and biological expression. By using unnatural amino acids and artificial protein backbones, our team is expanding what is biologically possible. Amide’s Automated Fast Flow Peptide Synthesizer (AFPS) leverages flow to dramatically improve solid phase peptide synthesis. Using the power of flow, we can generate highly reactive intermediates in situ, maintain excellent heat and mass transfer, and achieve much better synthetic outcomes than alternative SPPS methods. With all these advantages, AFPS allows biopharma pioneers to dramatically re-think what’s possible. Let Amide broaden your horizons with better, faster synthesis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $16.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2023)
- Website: amidetech.com
- Phone: 508-203-1367
Industries & Categories
Information Technology
Social Profiles
Canonical: https://fsome.com/organization/amide-technologies-63034 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.